261 related articles for article (PubMed ID: 36265568)
1. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
2. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
3. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
4. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
5. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T
J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443
[TBL] [Abstract][Full Text] [Related]
6. VISTA: Coming of age as a multi-lineage immune checkpoint.
ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
[TBL] [Abstract][Full Text] [Related]
7. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
8. VISTA expression and patient selection for immune-based anticancer therapy.
Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
Hou Z; Pan Y; Fei Q; Lin Y; Zhou Y; Liu Y; Guan H; Yu X; Lin X; Lu F; Huang H
J Cancer Res Clin Oncol; 2021 Feb; 147(2):517-531. PubMed ID: 33237432
[TBL] [Abstract][Full Text] [Related]
11. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
12. VISTA Regulates the Development of Protective Antitumor Immunity.
Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
[TBL] [Abstract][Full Text] [Related]
13. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
14. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
[TBL] [Abstract][Full Text] [Related]
15. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
16. Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors.
Chmiel P; Gęca K; Michalski A; Kłosińska M; Kaczyńska A; Polkowski WP; Pelc Z; Skórzewska M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373091
[TBL] [Abstract][Full Text] [Related]
17. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
[TBL] [Abstract][Full Text] [Related]
18. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes.
Vesely MD; Kidacki M; Gaule P; Gupta S; Chan NNN; Han X; Yeung JT; Chen L
J Invest Dermatol; 2024 Jan; 144(1):106-115.e4. PubMed ID: 37562584
[TBL] [Abstract][Full Text] [Related]
19. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]